Genomics and proteomics - The way forward

Annals of Oncology

Volumn 16, Issue SUPPL. 2, 2005, Pages

  Baak, J P A ^a,b,c   Janssen, E A M ^a   Soreide, K ^a   Heikkilae R ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; IMATINIB; TRASTUZUMAB;

ACCURACY; BRASSICA; BREAST CANCER; CANCER CELL; CANCER GENETICS; CANCER PREVENTION; CANCER SCREENING; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA HELIX; DNA MICROARRAY; DROSOPHILA; ELECTROPHORESIS; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC TRANSFECTION; GENOMICS; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN GENOME; KARYOTYPING; LUNG CANCER; MICROSATELLITE INSTABILITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN TARGETING; PROTEOMICS; REPRODUCIBILITY; REVIEW; RNA INTERFERENCE; RNA TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPECTRAL KARYOTYPING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; TRANSCRIPTOMICS; TUMOR CLASSIFICATION; TWO HYBRID SYSTEM; UTERINE CERVIX CANCER;

GENOMICS; GENOTYPE; HUMANS; NEOPLASMS; PATIENT CARE PLANNING; PHENOTYPE; PROGNOSIS; PROTEOMICS;

EID: 21344455355     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi728     Document Type: Review

References (104)

1. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953; 171: 737-738.
2. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-1351.
3. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
4. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003; 349: 996-998.
5. Conrads TP, Zhou M, Petricoin EF 3rd et al. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 2003; 3: 411-420.
6. Tyers M, Mann M. From genomics to proteomics. Nature 2003; 422: 193-197.
7. Futreal PA, Coin L, Marshall M et al. A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
8. Chen YC, Hunter DJ. Molecular epidemiology of cancer. CA Cancer J Clin 2005; 55: 45-54.
9. Sasco AJ. Migration and cancer. Rev Med Interne 1989; 10: 341-348.
10. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 2004; 292: 2977-2983.
11. Hong CC, Thompson HJ, Jiang C et al. Association between the T27C polymorphism in the cytochrome P450 c17alpha (CYP17) gene and risk factors for breast cancer. Breast Cancer Res Treat 2004; 88: 217-230.
12. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820-823.
13. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
14. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532.
15. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
17. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593-1603.
18. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-849.
19. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004; 432: 332-337.
20. Jacks T, Weinberg RA. Taking the study of cancer cell survival to a new dimension. Cell 2002; 111: 923-925.
21. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
22. Costea DE, Loro LL, Dimba EA et al. Crucial effects of fibroblasts and keratinocyte growth factor on morphogenesis of reconstituted human oral epithelium. J Invest Dermatol 2003; 121: 1479-1486.
23. Baak JP, Path FR, Hermsen MA et al. Genomics and proteomics in cancer. Eur J Cancer 2003; 39: 1199-1215.
24. Han W, Kang D, Park IA et al. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin Cancer Res 2004; 10: 124-130.
25. Huang J, Wei W, Zhang J et al. Whole genome DNA copy number changes identified by high density oligonucleotide arrays. Hum Genomics 2004; 1: 287-299.
26. Fire A, Xu S, Montgomery MK et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
27. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378.
28. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
29. Ziauddin J, Sabatini DM. Microarrays of cells expressing defined cDNAs. Nature 2001; 411: 107-110.
30. Erfle H, Simpson JC, Bastiaens PI, Pepperkok R. siRNA cell arrays for high-content screening microscopy. Biotechniques 2004; 37: 454-458. 460, 462.
31. Hong JW, Studer V, Hang G et al. A nanoliter-scale nucleic acid processor with parallel architecture. Nat Biotechnol 2004; 22: 435-439.
32. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
33. Krishna RG, Wold F. Posttranslational modifications. In Angeletti RH (ed.): Proteins-Analysis and Design. San Diego: Academic Press 1988; 121-206.
34. Zielinski GD, Bais AG, Helmerhorst TJ et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004; 59: 543-553.
35. van der Velden VH, Bruggemann M, Hoogeveen PG et al. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse. Leukemia 2004; 18: 1971-1980.
36. Feldman AL, Espina V, Petricoin EF 3rd et al. Use of proteomic patterns to screen for gastrointestinal malignancies. Surgery 2004; 135: 243-247.
37. Petricoin E, Wulfkuhle J, Espina V, Liotta LA. Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J Proteome Res 2004; 3: 209-217.
38. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267-275.
39. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572-577.
40. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005; 97: 307-309.
41. Posadas EM, Simpkins F, Liotta LA et al. Proteomic analysis for the early detection and rational treatment of cancer - realistic hope? Ann Oncol 2005; 16: 16-22.
42. Baak JP, Oort J. The case for quantitative pathology. In Baak JP (ed.): Manual of Cancer Diagnosis and Prognosis. New York: Springer 1991; 12-31.
43. Sloane JP, Amendoeira I, Apostolikas N et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 1999; 434: 3-10.
44. Baak JP. The framework of pathology: good laboratory practice by quantitative and molecular methods. J Pathol 2002; 198: 277-283.
45. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 2004; 165: 1057-1068.
46. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001; 98: 13790-13795.
47. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
48. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
49. Zhou W, Goodman SN, Galizia G et al. Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet 2002; 359: 219-225.
50. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-1837.
51. Centeno BA, Enkemann SA, Coppola D et al. Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer Cytopathology 2005; In press.
52. Isaacson PG, Du MQ. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol 2005; 205: 255-274.
53. Schraders M, de Jong D, Kluin P et al. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205: 329-335.
54. van Dongen JJ, Langerak AW, Bruggemann M et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
55. Bloom G, Yang IV, Boulware D et al. Multi-platform, multi-site, microarray-based human tumor classification. Am J Pathol 2004; 164: 9-16.
56. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
57. Jeronimo C, Usadel H, Henrique R et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93: 1747-1752.
58. Janssen EA, Baak JP, Guervos MA et al. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumour diameter, and oestrogen receptor. J Pathol 2003; 201: 555-561.
59. Shayesteh L, Lu Y, Kuo WL et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
60. Campbell IG, Russell SE, Choong DY et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-7681.
61. Lee JW, Soung YH, Kim SY et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24: 1477-1480.
62. Silvestrini R, Benini E, Veneroni S et al. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 1996; 14: 1604-1610.
63. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004; 57: 675-681.
64. Volpi A, Nanni O, De Paola F et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003; 21: 2708-2712.
65. Yu Y, Xu F, Peng H et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999; 96: 214-219.
66. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
67. Pandolfi PP. Breast cancer - loss of PTEN predicts resistance to treatment. N Engl J Med 2004; 351: 2337-2338.
68. Mutter GL, Lin MC, Fitzgerald JT et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.
69. Bruni P, Boccia A, Baldassarre G et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kip1. Oncogene 2000; 19: 3146-3155.
70. Goel A, Arnold CN, Niedzwiecki D et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 2004; 64: 3014-3021.
71. Baak JP, Orbo A, van Diest PJ et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25: 930-935.
72. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364: 1127-1134.
73. Eisenhauer EA. From the molecule to the clinic - inhibiting HER2 to treat breast cancer. N Engl J Med 2001; 344: 841-842.
74. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
75. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nat Rev Cancer 2004; 4: 956-965.
76. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340-4346.
77. Kurata T, Tamura K, Kaneda H et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol 2004; 15: 173-174.
78. Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 641-656, ix.
79. Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128: 270-279.
80. Lal P, Salazar PA, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. Am J Clin Pathol 2004; 121: 631-636.
81. Kruse AJ, Skaland I, Janssen EA et al. Quantitative molecular parameters to identify low-risk and high-risk early CIN lesions: role of markers of proliferative activity and differentiation and Rb availability. Int J Gynecol Pathol 2004; 23: 100-109.
82. Mutter GL, Baak JP, Crum CP et al. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 462-469.
83. Baak JP, Janssen E. DNA ploidy analysis in histopathology. Morphometry and DNA cytometry reproducibility conditions and clinical applications. Histopathology 2004; 44: 603-614.
84. Panigrahi AR, Pinder SE, Chan SY et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 2004; 204: 93-100.
85. Rhodes A, Jasani B, Balaton AJ, Miller KD. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol 2000; 53: 292-301.
86. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci, USA 2003; 100: 8621-8623.
87. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res 2001; 83: 1-54.
88. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 2002; 110: 9-12.
89. Attardi LD. The role of p53-mediated apoptosis as a crucial antitumor response to genomic instability: lessons from mouse models. Mutat Res 2005; 569: 145-157.
90. Oren M. Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell 1997; 90: 829-832.
91. Levine AJ, Finlay CA, Hinds PW. P53 is a tumor suppressor gene. Cell 2004; 116: S67-S69. 1 p following S69.
92. Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer 2003; 3: 869-876.
93. Ransohoff DF. Evaluating discovery-based research: when biologic reasoning cannot work. Gastroenterology 2004; 127: 1028.
94. Hall PA, Going JJ. Predicting the future: a critical appraisal of cancer prognosis studies. Histopathology 1999; 35: 489-494.
95. Yeatman TJ. The future of cancer management: translating the genome, transcriptome, and proteome. Ann Surg Oncol 2003; 10: 7-14.
96. Garber ME, Troyanskaya OG, Schluens K et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001; 98: 13784-13789.
97. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-492.
98. Rhodes DR, Yu J, Shanker K et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004; 101: 9309-9314.
99. Baak JP, Mutter GL. EIN and WHO94. J Clin Pathol 2005; 58: 1-6.
100. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000; 76: 287-290.
101. Hecht JL, Ince TA, Baak JP et al. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005; 18: 324-330.
102. Debes JD, Urrutia R. Bioinformatics tools to understand human diseases. Surgery 2004; 135: 579-585.
103. Hall PA, Lowe SW. Molecular and cellular themes in cancer research: II. J Pathol 2005; 205: 121-122.
104. Baak JP, van Diermen B, Steinbach A et al. Lack of PTEN expression in endometrial intraepithelial neoplasia (EIN) is correlated with cancer progression. Hum Pathol 2005; In press.